Navigation Links
Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Date:5/5/2009

e neuraminidase or "NA" proteins, which stimulate the body to produce antibodies that neutralize influenza virus and prevent spread throughout the cells of the respiratory tract -- and the matrix 1 or "M1" virus that stimulates cytotoxic T lymphocytes to kill cells that may already be infected. This three-pronged approach may offer an advantage over existing vaccines which contain mostly HA with variable and typically low quantities of NA and M1. Further, the VLPs are not made from a live virus and have no genetic material in their inner core, which renders them incapable of replicating and mixing with other influenza viruses.

The current study was planned before the recent outbreak of the 2009 H1N1 influenza virus in North America, which has since spread around the globe. In response to the outbreak, Novavax is making a VLP vaccine candidate against the outbreak strain. Using Novavax's recombinant technology, the VLPs will be genetically matched to the H1N1 influenza strain recommended by CDC, with the potential to induce specific and protective immunity. Further, the VLP approach has the potential of a rapid response as vaccine may be made and released for administration within 12 weeks of knowing the genetic sequence of the outbreak strain.

"We are delighted to have initiated the second clinical study of our seasonal influenza vaccine program", said Dr. Rahul Singhvi, President and CEO of Novavax. "The initiation of this study of the 2008-2009 VLP vaccine highlights our ability to create and manufacture VLPs against multiple influenza strains. Including this study, we now have created and evaluated the safety and immunogenicity of VLPs against seven different strains of influenza in clinical trials. This experience has been of great value as we continue our efforts to create a VLP vaccine against the recently emerged 2009 H1N1 influenza virus".

About Novavax

Novavax, Inc. is a clinical stag
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Novavax Announces Early Retirement of $17 Million of Convertible Debt
3. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
4. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
5. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
6. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
8. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
9. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
10. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
11. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... Q3 orders to $5.8 million and provides a good start to ... North America and one in the ... projects at record levels," said Peter Bruijns , President & ... end of Q3 than they have been for any complete year ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... has often been called "a game of inches," but biology ... a few nanometers can determine the fate of a cell ... cancerous. Scientists with the U.S. Department of Energy (DOE),s Lawrence ... better way to study the impact of spatial patterns on ...
... Calif., Nov. 1, 2011 Epitomics, Inc., a ... has received a Notice of Allowance from the ... Method for Identifying Differentially Expressed Proteins (application 10/705,109). ... differentially expressed proteins in cell samples using libraries ...
... DIEGO, Nov. 1, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... will present at the 20th Annual Credit Suisse Healthcare ... Time (7:00 AM Pacific Time). (Logo:   ... the presentation will be accessible on the Investors page ...
Cached Biology Technology:Berkeley Lab scientists develop new tool for the study of spatial patterns in living cells 2Berkeley Lab scientists develop new tool for the study of spatial patterns in living cells 3
(Date:10/15/2014)... assess the pandemic risk from strains of influenza virus ... allow ourselves to become complacent that the most substantial ... scientists. , Influenza pandemics arise when a new virus ... widespread immunity – spreads in the human population. There ... years, the worst of which – the 1918 Spanish ...
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
(Date:10/15/2014)... be awarded the 44th Rosenstiel Award for Distinguished Work ... research exploring the mechanisms of genomic instability and its ... is the second alumnus to win the Rosenstiel Award; ... 2003. , Alt is the Charles A. Janeway Professor ... School and an investigator at the Howard Hughes Medical ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... Scientists from Hungary, Germany and the U.K. have discovered that ... the active ingredient in marijuana (THC), but these play ... on "endocannabinoids" just published online in, and scheduled for the ... could lead to new drugs that treat skin conditions ranging ...
... Fla. -- A Florida State University faculty member ... class of cancer-killing drugs is attracting worldwide attention ... assistant professor of chemical and biomedical engineering at ... Engineering, is using high-powered computers to determine how ...
... University have found that quantum dot nanoparticles can penetrate ... into potential workplace concerns for healthcare workers or individuals ... research on potential biomedical applications of the tiny nanoparticles. ... different sizes, shapes and surface coatings do not penetrate ...
Cached Biology News:FSU researcher using computers to hone cancer-fighting strategies 2Study shows quantum dots can penetrate skin through minor abrasions 2
... Biosearch Technologies has been at the ... accelerate the discovery and application of ... FRET probes and primers or 100 ... applications, Biosearch can meet your most ...
Cultrex 3D Culture Matrix Rat Collagen I....
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
Cultrex 3D Culture Matrix Laminin I....
Biology Products: